Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/bs.mie.2017.06.006 http://scihub22266oqcxt.onion/10.1016/bs.mie.2017.06.006 C5705189!5705189 !28935106     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28935106 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28935106 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Methods+Enzymol 2017 ; 597 (ä): 265-281 Nephropedia Template TP {{tp|p=28935106 |t=2017. Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins |pdf=|usr=}}{{28935106 }} gab.com Text Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins JO: Methods Enzymol http://www.kidney.de/pget.php?&tw=1&pmid=28935106 #FOAvip N-glycosylation plays important roles in modulating the biological functions of glycoproteins, such as protein folding, stability, and immunogenicity. However, acquiring homogeneous glycoforms of glycoproteins has been a challenging task for functional studies and therapeutic applications. In this chapter, we describe an efficient chemoenzymatic glycan remodeling protocol for making homogeneous glycoproteins that involves enzymatic deglycosylation and subsequent reglycosylation procedures. Two therapeutic glycoproteins, Herceptin (trastuzumab, a therapeutic monoclonal antibody) and erythropoietin (EPO, a glycoprotein hormone), were chosen as the model systems. The detailed protocol includes the deglycosylation of the Herceptin or EPO with a wild-type endo-?-N-acetylglucosaminidase, to remove the heterogeneous N-glycans, leading to the GlcNAc-protein or Fuc?1,6GlcNAc-protein intermediate. Then desired homogeneous N-glycans are attached to the acceptor by using an activated sugar oxazoline as the donor substrate and a specific glycosynthase (mutant of endoglycosidase) as the catalyst to reconstitute a homogeneous glycoform. Using this approach, Herceptin was remodeled to an afucosylated complex glycoform and a Man(9)GlcNAc(2) glycoform, with the former showing significantly enhanced antibody-dependent cellular cytotoxicity. EPO was engineered to carry azide-tagged Man(3)GlcNAc(2) glycans that could be further modified via click chemistry to introduce other functional groups. Twit Text FOAVip Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins ????Methods Enzymol http://www.kidney.de/pget.php?&tw=1&pmid=28935106 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28935106 #FOAvip English Wikipedia <ref>{{Cite pmid|28935106 }}</ref> Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoproteins #MMPMID28935106 Yang Q ; Wang LX Methods Enzymol 2017[]; 597 (ä): 265-281 PMID28935106 show ga N-glycosylation plays important roles in modulating the biological functions of glycoproteins, such as protein folding, stability, and immunogenicity. However, acquiring homogeneous glycoforms of glycoproteins has been a challenging task for functional studies and therapeutic applications. In this chapter, we describe an efficient chemoenzymatic glycan remodeling protocol for making homogeneous glycoproteins that involves enzymatic deglycosylation and subsequent reglycosylation procedures. Two therapeutic glycoproteins, Herceptin (trastuzumab, a therapeutic monoclonal antibody) and erythropoietin (EPO, a glycoprotein hormone), were chosen as the model systems. The detailed protocol includes the deglycosylation of the Herceptin or EPO with a wild-type endo-?-N-acetylglucosaminidase, to remove the heterogeneous N-glycans, leading to the GlcNAc-protein or Fuc?1,6GlcNAc-protein intermediate. Then desired homogeneous N-glycans are attached to the acceptor by using an activated sugar oxazoline as the donor substrate and a specific glycosynthase (mutant of endoglycosidase) as the catalyst to reconstitute a homogeneous glycoform. Using this approach, Herceptin was remodeled to an afucosylated complex glycoform and a Man(9)GlcNAc(2) glycoform, with the former showing significantly enhanced antibody-dependent cellular cytotoxicity. EPO was engineered to carry azide-tagged Man(3)GlcNAc(2) glycans that could be further modified via click chemistry to introduce other functional groups. |Antibodies, Monoclonal/chemistry [MESH] |Erythropoietin/*chemistry/metabolism [MESH] |Glycoproteins/*chemistry/metabolism [MESH] |Glycoside Hydrolases/chemistry [MESH] |Glycosylation [MESH] |Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase/*chemistry [MESH] |Polysaccharides/chemistry [MESH] |Protein Engineering/*methods [MESH] |Protein Folding [MESH] |Recombinant Proteins/chemistry/metabolism [MESH]Chemoenzymatic Glycan Remodeling of Natural and Recombinant Glycoprote(epmc).pdf DeepDyve Pubget Overpricing